3/3
Immunology
Pursuing vaccines to stop celiac disease
Scientists at Penn’s Institute for RNA Innovation are using messenger RNA to stop the immune response that triggers celiac disease symptoms.
No evidence that CAR T cell therapy causes secondary cancers
In a new study, researchers at Penn Medicine looked for—and did not find—examples where the process of generating CAR T cells caused malignancy.
The compassionate team behind CAR T cancer breakthroughs
The clinical trial support staff at Penn Medicine and the Abramson Cancer Center have helped execute the team science that brings research discoveries from the lab bench to the bedside.
Scratching beneath the surface of itchy skin
Researchers from Penn Vet provide insights into how a species of worms found a way around the mammalian urge to scratch an itch.
An integral T cell pathway helps regulate female gene expression
Penn Vet researchers have revealed a connection between NF-κB signaling pathways and X chromosome inactivation, which has implications for understanding sex-based immune responses during infection.
Combo immunotherapy produces distinct waves of cancer-fighting T cells
Researchers from Penn’s Abramson Cancer Center have found that a novel tool that tracks immune health over time has revealed new insights on immune cell activation.
A newly identified immune checkpoint protein may lead to future cancer therapies
Penn Medicine researchers have found that knocking out a T cell’s CD5 gene greatly enhances the cell’s anticancer activity in a variety of preclinical cancer models.
New ‘armored’ CAR therapy produces significant responses in cancer patients
For patients whose cancers don't respond to current CAR T cell therapies, a new, modified CAR T cell therapy by Penn’s Carl June shows promise in a phase 1 clinical trial.
Honoring a life scientist’s lifesaving science
Carl June accepted the 2024 Breakthrough Prize in Life Sciences at a Los Angeles ceremony, making him the sixth recipient from Penn.
Study reveals inequities in access to transformative CAR T cell therapy
Penn Medicine researchers have assessed the percentage of patients from minority health populations and reveal inequities in access to transformative CAR T cell therapy.
In the News
‘Anti-vaxxers existed before, but never led governments’
In a Q&A, Drew Weissman of the Perelman School of Medicine says that a rise in anti-vaxxers could lead to deaths from preventable diseases like measles and polio, reversing decades of progress.
FULL STORY →
Why do women live longer than men?
Montserrat Anguera of the School of Veterinary Medicine says that epigenetic factors like climate or chronic stress may also play a role in life span, widening or shrinking the disparities between men and women.
FULL STORY →
Scientists are racing to develop a new bird flu vaccine
Drew Weissman and Scott Hensley of the Perelman School of Medicine are testing a vaccine to prevent a strain of H5N1 bird flu in chickens and cattle.
FULL STORY →
California declares a state of emergency as a new severe bird flu case was discovered. What it means for the rest of the country
Scott Hensley of the Perelman School of Medicine says the latest H5N1 bird flu strain might have a greater potential to adapt and cause severe disease in humans.
FULL STORY →
Keto diet supplement could boost a cancer treatment's effectiveness
A study by Perelman School of Medicine student Puneeth Guruprasad and postdoc Shan Liu suggests that a component of the keto diet could boost CAR T cell therapy to help treat cancer.
FULL STORY →
A beneficial bacterium helps wounds heal
Research by Ellen White of the Perelman School of Medicine and colleagues in Elizabeth Grice’s lab suggests that a bacterium found in chronic wounds can aid healing.
FULL STORY →